Van T, Minejima E, Chiu C, Butler-Wu S
J Clin Microbiol. 2019; 57(11).
PMID: 31645412
PMC: 6813016.
DOI: 10.1128/JCM.01268-19.
Ruiz J
Clin Microbiol Rev. 2019; 32(4).
PMID: 31413045
PMC: 6730498.
DOI: 10.1128/CMR.00007-19.
Franco A, Leekitcharoenphon P, Feltrin F, Alba P, Cordaro G, Iurescia M
PLoS One. 2015; 10(12):e0144802.
PMID: 26716443
PMC: 4696813.
DOI: 10.1371/journal.pone.0144802.
Sjolund-Karlsson M, Howie R, Crump J, Whichard J
J Clin Microbiol. 2014; 52(3):877-84.
PMID: 24391204
PMC: 3957759.
DOI: 10.1128/JCM.02679-13.
Guillard T, Cambau E, Chau F, Massias L, De Champs C, Fantin B
Antimicrob Agents Chemother. 2013; 57(12):5830-5.
PMID: 24018262
PMC: 3837926.
DOI: 10.1128/AAC.01489-13.
Nalidixic acid-resistant strains of Salmonella showing decreased susceptibility to fluoroquinolones in the midwestern region of the Republic of Ireland due to mutations in the gyrA gene.
Ryan M, Dillon C, Adley C
J Clin Microbiol. 2011; 49(5):2077-9.
PMID: 21389151
PMC: 3122662.
DOI: 10.1128/JCM.02574-10.
Fitness costs and stability of a high-level ciprofloxacin resistance phenotype in Salmonella enterica serotype enteritidis: reduced infectivity associated with decreased expression of Salmonella pathogenicity island 1 genes.
ORegan E, Quinn T, Frye J, Pages J, Porwollik S, Fedorka-Cray P
Antimicrob Agents Chemother. 2009; 54(1):367-74.
PMID: 19917752
PMC: 2798541.
DOI: 10.1128/AAC.00801-09.
Impact of low-level resistance to fluoroquinolones due to qnrA1 and qnrS1 genes or a gyrA mutation on ciprofloxacin bactericidal activity in a murine model of Escherichia coli urinary tract infection.
Allou N, Cambau E, Massias L, Chau F, Fantin B
Antimicrob Agents Chemother. 2009; 53(10):4292-7.
PMID: 19635960
PMC: 2764221.
DOI: 10.1128/AAC.01664-08.
Multiple regulatory pathways associated with high-level ciprofloxacin and multidrug resistance in Salmonella enterica serovar enteritidis: involvement of RamA and other global regulators.
ORegan E, Quinn T, Pages J, McCusker M, Piddock L, Fanning S
Antimicrob Agents Chemother. 2008; 53(3):1080-7.
PMID: 19104017
PMC: 2650546.
DOI: 10.1128/AAC.01005-08.
Characteristics of non-typhoidal Salmonella isolates from human and broiler-chickens in southwestern Seoul, Korea.
Cheong H, Lee Y, Hwang I, Kee S, Cheong H, Song J
J Korean Med Sci. 2007; 22(5):773-8.
PMID: 17982221
PMC: 2693839.
DOI: 10.3346/jkms.2007.22.5.773.
New quinolone resistance phenomenon in Salmonella enterica: nalidixic acid-susceptible isolates with reduced fluoroquinolone susceptibility.
Hakanen A, Lindgren M, Huovinen P, Jalava J, Siitonen A, Kotilainen P
J Clin Microbiol. 2005; 43(11):5775-8.
PMID: 16272517
PMC: 1287832.
DOI: 10.1128/JCM.43.11.5775-5778.2005.
In vitro activities of 11 fluoroquinolones against 816 non-typhoidal strains of Salmonella enterica isolated from Finnish patients with special reference to reduced ciprofloxacin susceptibility.
Kotilainen P, Pitkanen S, Siitonen A, Huovinen P, Hakanen A
Ann Clin Microbiol Antimicrob. 2005; 4:12.
PMID: 16143044
PMC: 1208849.
DOI: 10.1186/1476-0711-4-12.
Increasing prevalence of quinolone resistance in human nontyphoid Salmonella enterica isolates obtained in Spain from 1981 to 2003.
Marimon J, Gomariz M, Zigorraga C, Cilla G, Perez-Trallero E
Antimicrob Agents Chemother. 2004; 48(10):3789-93.
PMID: 15388435
PMC: 521902.
DOI: 10.1128/AAC.48.10.3789-3793.2004.
Mutations in topoisomerase genes of fluoroquinolone-resistant salmonellae in Hong Kong.
Ling J, Chan E, Lam A, Cheng A
Antimicrob Agents Chemother. 2003; 47(11):3567-73.
PMID: 14576119
PMC: 253778.
DOI: 10.1128/AAC.47.11.3567-3573.2003.
Is it time to change fluoroquinolone breakpoints for Salmonella spp.?.
Aarestrup F, Wiuff C, Molbak K, Threlfall E
Antimicrob Agents Chemother. 2003; 47(2):827-9.
PMID: 12543704
PMC: 151776.
DOI: 10.1128/AAC.47.2.827-829.2003.
Excess mortality associated with antimicrobial drug-resistant Salmonella typhimurium.
Helms M, Vastrup P, Gerner-Smidt P, Molbak K
Emerg Infect Dis. 2002; 8(5):490-5.
PMID: 11996684
PMC: 2732497.
DOI: 10.3201/eid0805.010267.
Comparison of gyrA mutations, cyclohexane resistance, and the presence of class I integrons in Salmonella enterica from farm animals in England and Wales.
Liebana E, Clouting C, Cassar C, Randall L, Walker R, Threlfall E
J Clin Microbiol. 2002; 40(4):1481-6.
PMID: 11923377
PMC: 140356.
DOI: 10.1128/JCM.40.4.1481-1486.2002.
Reduced fluoroquinolone susceptibility in Salmonella enterica serotypes in travelers returning from Southeast Asia.
Hakanen A, Kotilainen P, Huovinen P, Helenius H, Siitonen A
Emerg Infect Dis. 2001; 7(6):996-1003.
PMID: 11747728
PMC: 2631904.
DOI: 10.3201/eid0706.010613.
Use of a LightCycler gyrA mutation assay for rapid identification of mutations conferring decreased susceptibility to ciprofloxacin in multiresistant Salmonella enterica serotype Typhimurium DT104 isolates.
Walker R, Saunders N, Lawson A, Lindsay E, Dassama M, Ward L
J Clin Microbiol. 2001; 39(4):1443-8.
PMID: 11283069
PMC: 87952.
DOI: 10.1128/JCM.39.4.1443-1448.2001.
Detection of decreased fluoroquinolone susceptibility in Salmonellas and validation of nalidixic acid screening test.
Hakanen A, Kotilainen P, Jalava J, Siitonen A, Huovinen P
J Clin Microbiol. 1999; 37(11):3572-7.
PMID: 10523554
PMC: 85694.
DOI: 10.1128/JCM.37.11.3572-3577.1999.
